A Randomized, Double-blind, Phase III Study Evaluating Fixed Dose, Once-Per-Cycle Pegylated Filgrastim (SD/01) vs Daily Filgrastim to Support Chemotherapy for Breast Cancer

James Metz, MD

University of Pennsylvania Cancer
Ultima Vez Modificado: 12 de mayo del 2001

Translation for this article does not exist